---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-090821"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2024-04-09T23:59:59+00:00"
generated_at: "2026-06-04T00:59:13.140044+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Enliven Therapeutics appoints Dr. Lori Kunkel to Board of Directors

## Summary
- Dr. Kunkel appointed as Class III director, term expiring at 2026 annual meeting.
- Annual cash retainer of $35,000; stock option grant with fair value ~$500,000 vesting monthly over 3 years.
- No arrangements or transactions requiring disclosure under Item 404(a) of Reg S-K.
- Dr. Kunkel brings 25+ years oncology drug development experience; previously scientific advisor to Enliven.

## SEC filing metadata
- accession: 0001193125-24-090821
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2024-04-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312524090821/0001193125-24-090821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312524090821/d816494d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-090821
- JSON: https://secwatch.observer/filing/0001193125-24-090821.json
- Plain text: https://secwatch.observer/filing/0001193125-24-090821.txt

## Key facts
- Executive change
  Lori Kunkel was appointed as Class III Director at Enliven Therapeutics, Inc..
  - Action: appointed
  - Role: Class III Director
  source text: On April 8, 2024, the Board of Directors (the “Board”) of Enliven Therapeutics, Inc. (the “Company”) appointed Lori Kunkel, MD to serve as a Class III director, with a term expiring at the Company’s 2026 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000119312524090821/0001193125-24-090821-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.